- Home
- WSBF vs ITOS Comparison
WSBF vs ITOS Comparison
Compare WSBF & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSBF
- ITOS
- Stock Information
- Founded
- WSBF 1921
- ITOS 2011
- Country
- WSBF United States
- ITOS United States
- Employees
- WSBF N/A
- ITOS N/A
- Industry
- WSBF Savings Institutions
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WSBF Finance
- ITOS Health Care
- Exchange
- WSBF Nasdaq
- ITOS Nasdaq
- Market Cap
- WSBF 269.9M
- ITOS 270.7M
- IPO Year
- WSBF N/A
- ITOS 2020
- Fundamental
- Price
- WSBF $13.56
- ITOS $5.97
- Analyst Decision
- WSBF
- ITOS Strong Buy
- Analyst Count
- WSBF 0
- ITOS 3
- Target Price
- WSBF N/A
- ITOS $26.00
- AVG Volume (30 Days)
- WSBF 37.9K
- ITOS 366.6K
- Earning Date
- WSBF 04-29-2025
- ITOS 03-05-2025
- Dividend Yield
- WSBF 4.46%
- ITOS N/A
- EPS Growth
- WSBF 118.94
- ITOS N/A
- EPS
- WSBF 1.01
- ITOS N/A
- Revenue
- WSBF $135,638,000.00
- ITOS $35,000,000.00
- Revenue This Year
- WSBF N/A
- ITOS N/A
- Revenue Next Year
- WSBF N/A
- ITOS $121.70
- P/E Ratio
- WSBF $13.36
- ITOS N/A
- Revenue Growth
- WSBF 3.74
- ITOS 177.89
- 52 Week Low
- WSBF $10.60
- ITOS $5.85
- 52 Week High
- WSBF $16.86
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- WSBF 45.61
- ITOS 29.75
- Support Level
- WSBF $13.29
- ITOS $6.32
- Resistance Level
- WSBF $13.76
- ITOS $6.76
- Average True Range (ATR)
- WSBF 0.33
- ITOS 0.34
- MACD
- WSBF -0.02
- ITOS -0.09
- Stochastic Oscillator
- WSBF 47.22
- ITOS 6.67
About WSBF Waterstone Financial Inc. (MD)
Waterstone Financial Inc is a holding company. Through its subsidiaries, It operates in two segments: Community Banking and Mortgage Banking. The community banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The vast majority of its revenue comes from the community banking segment.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.